Literature DB >> 12534514

Combined ultrapulse CO2 laser and Q-switched alexandrite laser compared with Q-switched alexandrite laser alone for refractory melasma: split-face design.

Suhattaya Angsuwarangsee1, Niwat Polnikorn.   

Abstract

BACKGROUND: : Melasma is common and can cause major psychological impact. To date, the mainstay of treatment, including various hypopigmenting agents and chemical peels, is ineffective and can cause adverse effects. Laser is a new approach and is yet to be explored for its efficacy and safety.
OBJECTIVE: : To compare combined Ultrapulse CO2 laser and Q-switched alexandrite laser (QSAL) with QSAL alone in the treatment of refractory melasma.
METHODS: : Six Thai females were treated with combined Ultrapulse CO2 laser and QSAL on one side of the face and QSAL alone on the other side. The outcome was evaluated periodically for up to 6 months using the modified Melasma Area and Severity Index score and the modified Melasma Area and Melanin Index score.
RESULTS: : The side with combination treatment had a statistically significant reduction of both scores. On the QSAL side, the score reduction was not significant. Two cases developed severe postinflammatory hyperpigmentation and were effectively treated with bleaching agents. Transient hypopigmentation and contact dermatitis were observed with the combination treatment side.
CONCLUSIONS: : Combined Ultrapulse CO2 laser and QSAL showed a better result than QSAL alone but was associated with more frequent adverse effects. Long-term follow-up and a larger number of cases are required to determine its efficacy and safety for refractory melasma.

Entities:  

Mesh:

Year:  2003        PMID: 12534514     DOI: 10.1046/j.1524-4725.2003.29009.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  18 in total

Review 1.  [Fractional photothermolysis: a new option for treating melasma?].

Authors:  S Karsai; C Raulin
Journal:  Hautarzt       Date:  2008-02       Impact factor: 0.751

2.  Low Fluence Q-Switched Nd: YAG Laser Toning and Q-Switched Ruby Laser in the Treatment of Melasma:A Comparative Split-Face Ultrastructural Study.

Authors:  Tokuya Omi; Rie Yamashita; Seiji Kawana; Shigeru Sato; Zenya Naito
Journal:  Laser Ther       Date:  2012-03-28

3.  Combination of Q-Switched Nd:YAG and Fractional Erbium:YAG Lasers in Treatment of Melasma: A Randomized Controlled Clinical Trial.

Authors:  Shiva Alavi; Ehsan Abolhasani; Sharin Asadi; Mohammadali Nilforoushzadeh
Journal:  J Lasers Med Sci       Date:  2017-01-08

4.  The Asian Problem of Frequent Laser Toning for Melasma.

Authors:  Brian Tian
Journal:  J Clin Aesthet Dermatol       Date:  2017-07-01

5.  The dual toning technique for melasma treatment with the 1064 nm Nd: YAG laser: A preliminary study.

Authors:  Hy Kang; Jh Kim; Bc Goo
Journal:  Laser Ther       Date:  2011

6.  Melasma and low-energy Q-switched laser: treatment assessment by means of in vivo confocal microscopy.

Authors:  Caterina Longo; Giovanni Pellacani; Athanasia Tourlaki; Michela Galimberti; Pier Luca Bencini
Journal:  Lasers Med Sci       Date:  2013-11-30       Impact factor: 3.161

7.  Lasers are not Effective for Melasma in Darkly Pigmented Skin.

Authors:  Kabir Sardana; Vijay K Garg
Journal:  J Cutan Aesthet Surg       Date:  2014-01

8.  Lasers for treatment of melasma and post-inflammatory hyperpigmentation.

Authors:  Pooja Arora; Rashmi Sarkar; Vijay K Garg; Latika Arya
Journal:  J Cutan Aesthet Surg       Date:  2012-04

Review 9.  The use of ablative lasers in the treatment of facial melasma.

Authors:  Orlando Oliveira de Morais; Érica Freitas Lima Lemos; Márcia Carolline dos Santos Sousa; Ciro Martins Gomes; Izelda Maria Carvalho Costa; Carmen Déa Ribeiro de Paula
Journal:  An Bras Dermatol       Date:  2013 Mar-Apr       Impact factor: 1.896

10.  Treatment of melasma in Caucasian patients using a novel 694-nm Q-switched ruby fractional laser.

Authors:  Said Hilton; Heike Heise; Bettina Alexandra Buhren; Holger Schrumpf; Edwin Bölke; Peter Arne Gerber
Journal:  Eur J Med Res       Date:  2013-11-14       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.